Literature DB >> 9351505

Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases.

W Neupert1, R Brugger, C Euchenhofer, K Brune, G Geisslinger.   

Abstract

1. Ibuprofen enantiomers and their respective coenzyme A thioesters were tested in human platelets and blood monocytes to determine their selectivity and potency as inhibitors of cyclo-oxygenase activity of prostaglandin endoperoxide synthase-1 (PGHS-1) and PGHS-2. 2. Human blood from volunteers was drawn and allowed to clot at 37 degrees C for 1 h in the presence of increasing concentrations of the test compounds (R-ibuprofen, S-ibuprofen, R-ibuprofenoyl-CoA, S-ibuprofenoyl-CoA, NS-398). Immunoreactive (ir) thromboxane B2 (TXB2) concentrations in serum were determined by a specific EIA assay as an index of the cyclo-oxygenase activity of platelet PGHS-1. 3. Heparin-treated blood from the same donors was incubated at 37 degrees C for 24 h with the same concentrations of the test compounds in the presence of lipopolysaccharide (LPS, 10 microg ml[-1]). The contribution of PGHS-1 was suppressed by pretreatment of the volunteers with aspirin (500 mg; 48 h before venepuncture). As a measure of LPS induced PGHS-2 activity immunoreactive prostaglandin E2 (irPGE2) plasma concentrations were determined by a specific EIA assay. 4. S-ibuprofen inhibited the activity of PGHS-1 (IC50 2.1 microM) and PGHS-2 (IC50 1.6 microM) equally. R-ibuprofen inhibited PGHS-1 (IC50 34.9) less potently than S-ibuprofen and showed no inhibition of PGHS-2 up to 250 microM. By contrast R-ibuprofenoyl-CoA thioester inhibited PGE2 production from LPS-stimulated monocytes almost two orders of magnitude more potently than the generation of TXB2 (IC50 5.6 vs 219 microM). 5. Western blotting of PGHS-2 after LPS induction of blood monocytes showed a concentration-dependent inhibition of PGHS-2 protein expression by ibuprofenoyl-CoA thioesters. 6. These data confirm that S-ibuprofen represents the active entity in the racemate with respect to cyclo-oxygenase activity. More importantly the data suggest a contribution of the R-enantiomer to therapeutic effects not only by chiral inversion to S-ibuprofen but also via inhibition of induction of PGHS-2 mediated by R-ibuprofenoyl-CoA thioester. 7. The data may explain why racemic ibuprofen is ranked as one of the safest non-steroidal anti-inflammatory drugs (NSAIDs) so far determined in epidemiological studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351505      PMCID: PMC1564971          DOI: 10.1038/sj.bjp.0701415

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

Review 1.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

2.  Effect of a cyclooxygenase-2 inhibitor on postexercise muscle protein synthesis in humans.

Authors:  Nicholas A Burd; Jared M Dickinson; Jennifer K Lemoine; Chad C Carroll; Bridget E Sullivan; Jacob M Haus; Bozena Jemiolo; Scott W Trappe; Gordon M Hughes; Charles E Sanders; Todd A Trappe
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-24       Impact factor: 4.310

3.  Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.

Authors:  Carolina de Miranda Silva; Adriana Rocha; Eduardo Tozatto; Lucienir Maria da Silva; Eduardo Antônio Donadi; Teresa Dalla Costa; Vera Lucia Lanchote; Stephan Schmidt; Jürgen B Bulitta
Journal:  AAPS J       Date:  2017-09-05       Impact factor: 4.009

Review 4.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

5.  Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate.

Authors:  J Lötsch; U Muth-Selbach; I Tegeder; K Brune; G Geisslinger
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

6.  Gastric toxicity of racemic ketoprofen and its enantiomers in rat: oxygen radical generation and COX-expression.

Authors:  C Alarcón de la Lastra; A Nieto; M J Martín; F Cabré; J M Herrerías; V Motilva
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

7.  PharmGKB summary: ibuprofen pathways.

Authors:  Liudmila L Mazaleuskaya; Katherine N Theken; Li Gong; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

8.  Albumin-Based Transport of Nonsteroidal Anti-Inflammatory Drugs in Mammalian Blood Plasma.

Authors:  Mateusz P Czub; Katarzyna B Handing; Barat S Venkataramany; David R Cooper; Ivan G Shabalin; Wladek Minor
Journal:  J Med Chem       Date:  2020-06-17       Impact factor: 7.446

Review 9.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

10.  Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells.

Authors:  Simona Bancos; Matthew P Bernard; David J Topham; Richard P Phipps
Journal:  Cell Immunol       Date:  2009-04-05       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.